PML-RARA t(15;17) Gene Rearrangement Quantitative MRD Monitor Test
Understanding the PML-RARA Gene Rearrangement Test
The PML-RARA t(15;17) Gene Rearrangement Quantitative MRD Monitor Test represents a breakthrough in molecular diagnostics for Acute Promyelocytic Leukemia (APL) management. This sophisticated test specifically targets the unique genetic abnormality that defines APL – the translocation between chromosomes 15 and 17, which creates the PML-RARA fusion gene. This genetic alteration is not just a diagnostic marker but plays a central role in the disease’s pathogenesis and response to targeted therapies.
What This Advanced Test Measures
This quantitative molecular test precisely detects and measures the presence of the PML-RARA fusion gene using cutting-edge Real-Time PCR technology. The test provides:
- Detection of the specific t(15;17) chromosomal translocation
- Quantitative measurement of PML-RARA fusion gene expression levels
- High-sensitivity monitoring of minimal residual disease (MRD)
- Precise tracking of treatment response over time
- Early identification of molecular relapse before clinical symptoms appear
Who Should Consider This Test?
This specialized test is essential for patients diagnosed with or suspected of having Acute Promyelocytic Leukemia. Specific indications include:
- Patients with confirmed APL diagnosis for baseline assessment
- Individuals undergoing treatment with all-trans retinoic acid (ATRA) or arsenic trioxide
- Patients in remission to monitor for minimal residual disease
- Those with suspected molecular relapse despite clinical remission
- Individuals with abnormal bleeding tendencies or coagulation issues suggestive of APL
- Patients with previous APL history requiring long-term monitoring
Clinical Symptoms and Indicators
Patients experiencing symptoms such as unexplained bleeding tendencies, easy bruising, petechiae, fatigue, recurrent infections, or abnormal blood counts should discuss this test with their hematologist. Early detection and monitoring can significantly impact treatment outcomes and quality of life.
Significant Benefits of MRD Monitoring
Regular monitoring with the PML-RARA Quantitative MRD Test offers numerous advantages:
- Early Relapse Detection: Identifies molecular relapse months before clinical symptoms appear
- Treatment Optimization: Guides therapy adjustments based on quantitative response data
- Prognostic Information: Provides valuable insights into long-term outcomes
- Personalized Care: Enables tailored treatment approaches for individual patients
- Peace of Mind: Offers reassurance through regular monitoring and early intervention capabilities
Understanding Your Test Results
Your quantitative MRD results will provide crucial information about your treatment response and disease status:
- Negative Result: No detectable PML-RARA fusion gene indicates molecular remission
- Low-Level Detection: Minimal residual disease may require continued monitoring
- Increasing Levels: Rising PML-RARA levels may indicate impending relapse
- Persistent Positivity: Ongoing detection suggests treatment resistance
Your hematologist will interpret these results in the context of your clinical status and treatment history to make informed decisions about your care plan.
Test Pricing and Availability
| Test Name | Regular Price | Discount Price |
|---|---|---|
| PML-RARA t(15;17) Gene Rearrangement Quantitative MRD Monitor Test | $170 USD | $152 USD |
Sample Requirements and Processing
Sample Type: 5 mL (3 mL minimum) whole blood or bone marrow in 1 Lavender Top (EDTA) tube
Shipping Instructions: Ship refrigerated. DO NOT FREEZE
Mandatory Documentation: Duly filled MRD Requisition form (Form 22) with historical data is required
Turnaround Time: Samples accepted Monday, Wednesday, Friday by 9 AM; Reports delivered Tuesday, Thursday, Saturday
Nationwide Availability
We have diagnostic centers conveniently located across the United States, serving patients in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more. Our network ensures accessible, high-quality molecular diagnostics for patients nationwide.
Take Control of Your Health Today
Don’t wait to get the crucial information you need for effective APL management. Our PML-RARA Quantitative MRD Monitor Test provides the precision monitoring required for optimal treatment outcomes. With our discounted price of $152 USD and convenient locations across the USA, there’s no reason to delay this important health assessment.
Ready to schedule your test? Contact us today at +1(267) 388-9828 or book your appointment online. Our specialized team is ready to assist you with this advanced molecular diagnostic service.
